Founder, CEO and Executive Chairman
Dr. Hood is a veteran of the California life science community who has founded and led several successful biotechnology companies in his 20-year career. He is currently Founder, CEO and Executive Chairman of Endeavor Biomedicines, a company funded in 2021 to develop novel therapeutics for oncology and idiopathic pulmonary fibrosis. Prior to that, John was the Founder and CEO of Impact Biomedicines (now owned by Bristol-Myers Squibb), the developer of fedratinib, which has subsequently been approved worldwide for the treatment of myelofibrosis. He began his career as Director of Research at TargeGen in 2001, where he co-discovered fedratinib and led a team identifying small molecule therapeutics for the treatment of cancer and eye disease. John is an inventor on 100+ patents and the author of 50+ scientific articles. He received his Ph.D. in Medical Physiology and a B.S. in Biochemistry from Texas A&M University.